Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 32-40 , April 2010

Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis

  • Janneke P.C. Grutters

      Affiliations

    • Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Maastricht University, Dept. of Health Organization, Policy and Economics, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
    • ,
  • Alfons G.H. Kessels

      Affiliations

    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, The Netherlands
    • ,
  • Madelon Pijls-Johannesma

      Affiliations

    • Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre, The Netherlands
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre, The Netherlands
    • ,
  • Manuela A. Joore

      Affiliations

    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre, The Netherlands
    • These authors contributed equally to this work.

Received 18 March 2009 ,Revised 8 July 2009 ,Accepted 1 August 2009.

References 

  1. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–970
  2. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83:110–122
  3. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy – a systematic review of clinical effectiveness. Radiother Oncol. 2007;83:123–132
  4. Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Particle therapy in lung cancer: where do we stand? Cancer Treat Rev. 2008;34:259–267
  5. Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. Radiother Oncol. 2008;86:154–164
  6. Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue?. Radiother Oncol. 2008;86:142–147
  7. Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol. 2008;26:2438–2439
  8. Glimelius B, Montelius A. Proton beam therapy – do we need the randomised trials and can we do them?. Radiother Oncol. 2007;83:105–109
  9. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  10. Tepper JE. Protons and parachutes. J Clin Oncol. 2008;26:2436–2437
  11. Anonymous. Introducing new treatments and technologies into the clinic. J Clin Oncol 2008;26:2425.
  12. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008;86:148–153
  13. Morgan, JP. A patient’s perspective on randomized clinical trials for proton radiotherapy. J Clin Oncol 2008;26:2592.
  14. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist. 2008;13:309–319
  15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012
  16. Auperin A, Rolland E, Curran WJ, et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol. 2007;2:S310
  17. Rowell NP, O’Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004;4:CD002140
  18. Bentzen SM, Saunders MI, Dische S. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. Clin Oncol [R Coll Radiol]. 2002;14:372–381
  19. National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf.2006.
  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  21. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585–598
  22. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694
  23. Hoyer M, Roed H, Hansen AT, et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:S128–S135
  24. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  25. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–100
  26. Fukumoto S, Shirato H, Shimzu S, et al. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas. Cancer. 2002;95:1546–1553
  27. Hiraoka M, Matsuo Y, Nagata Y. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer. Cancer Radiother. 2007;11:32–35
  28. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–1431
  29. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose–response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:374–381
  30. Onishi H, Kuriyama K, Komiyama T, et al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer. 2004;45:45–55
  31. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  32. Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest. 1995;108:1278–1282
  33. Lagerwaard FJ, Senan S, van Meerbeeck JP, Graveland WJ. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. Radiother Oncol. 2002;63:151–157
  34. Morita K, Fuwa N, Suzuki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol. 1997;42:31–36
  35. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–154
  36. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:1047–1057
  37. Hayakawa K, Mitsuhashi N, Saito Y, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  38. Krol AD, Aussems P, Noordijk EM, Hermans J, Leer JW. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys. 1996;34:297–302
  39. Bradley JD, Wahab S, Lockett MA, Perez CA, Purdy JA. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys. 2003;56:342–347
  40. Din OS, Lester J, Cameron A, et al. Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience. Int J Radiat Oncol Biol Phys. 2008;72:716–722
  41. Fang LC, Komaki R, Allen P, Guerrero T, Mohan R, Cox JD. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:108–116
  42. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1997;38:521–525
  43. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–434
  44. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–692
  45. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103
  46. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670
  47. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125
  48. Zimmermann FB, Geinitz H, Schill S. Et al. Stereotactic hypofractionated radiotherapy in stage I (T1–2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45:796–801
  49. Scorsetti M, Navarria P, Facoetti A, et al. Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. Anticancer Res. 2007;27:3615–3619
  50. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  51. Salazar OM, Sandhu TS, Lattin PB, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2008;72:707–715
  52. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999;116:1313–1319
  53. Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126:1198–1203
  54. Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys. 2007;68:786–793
  55. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:107–111
  56. Shioyama Y, Tokuuye K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:7–13
  57. Miyamoto T, Baba M, Sugane T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007;2:916–926
  58. Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys. 2007;67:750–758
  59. Miyamoto T, Yamamoto N, Nishimura H, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003;66:127–140
  60. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–1375
  61. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28:1–9
  62. Hoyer M. Improved accuracy and outcome in radiotherapy of lung cancer. Radiother Oncol. 2008;87:1–2
  63. Cox JD, Chang J, Liao Z, et al. Acute esophageal reactions from proton beam therapy, concurrent chemotherapy for non-small cell lung cancer (NSCLC): reduction in incidence, severity despite higher doses. J Thorac Oncol. 2007;2:S449
  64. Komaki R, Sejpal SV, Wei X, et al. Reduction of bone marrow suppression for patients with stage III NSCLC treated by proton and chemotherapy compared with IMRT and chemotherapy. Conference of the Particle Therapy Co-operative Group, vol. 47. Jacksonville, Florida; 2008. p. 14.
  65. Sejpal SV, Komaki R, Wei X, et al. Does proton beam radiotherapy (PBT) reduce treatment related pneumonitis (TRP) compared to intensity modulated related radiation therapy (IMRT) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy? Conference of the Particle Therapy Co-operative Group, vol. 47. Jacksonville, Florida; 2008. p. 22.
  66. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:119–130
  67. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11
  68. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56:628–638
  69. Zimmermann FB, Bamberg M, Molls M, Jeremic B. Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol. 2003;21:91–97
  70. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vincent VH. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev. 2008;34:719–727

PII: S0167-8140(09)00436-8

doi: 10.1016/j.radonc.2009.08.003

Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 32-40 , April 2010

Article Tools

* Image Usage & Resolution